SG11201406492YA - Optimised subcutaneous therapeutic agents - Google Patents

Optimised subcutaneous therapeutic agents

Info

Publication number
SG11201406492YA
SG11201406492YA SG11201406492YA SG11201406492YA SG11201406492YA SG 11201406492Y A SG11201406492Y A SG 11201406492YA SG 11201406492Y A SG11201406492Y A SG 11201406492YA SG 11201406492Y A SG11201406492Y A SG 11201406492YA SG 11201406492Y A SG11201406492Y A SG 11201406492YA
Authority
SG
Singapore
Prior art keywords
optimised
therapeutic agents
subcutaneous therapeutic
subcutaneous
agents
Prior art date
Application number
SG11201406492YA
Inventor
William Henry
Richard Wolf-Garraway
John Charles Mayo
Michael James Earl
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en
Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en
Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of SG11201406492YA publication Critical patent/SG11201406492YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
SG11201406492YA 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents SG11201406492YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en) 2012-08-01 2012-08-01 Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en) 2012-08-22 2012-08-22 Modified therapeutic agents
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Publications (1)

Publication Number Publication Date
SG11201406492YA true SG11201406492YA (en) 2014-11-27

Family

ID=48190923

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406492YA SG11201406492YA (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents

Country Status (29)

Country Link
US (2) US20150086524A1 (en)
EP (1) EP2838566A2 (en)
JP (3) JP2015512927A (en)
KR (1) KR102137290B1 (en)
CN (1) CN104411335A (en)
AP (1) AP2014008049A0 (en)
AU (3) AU2013248296A1 (en)
BR (1) BR112014025737A2 (en)
CA (1) CA2869993C (en)
CL (1) CL2014002773A1 (en)
CO (1) CO7151496A2 (en)
CR (1) CR20140475A (en)
EA (1) EA033469B1 (en)
EC (1) ECSP14023048A (en)
GB (3) GB2516388A (en)
GE (1) GEP201706716B (en)
HK (1) HK1200695A1 (en)
IL (1) IL235129B (en)
IN (1) IN2014DN08598A (en)
MD (1) MD20140123A2 (en)
MX (2) MX2014012512A (en)
MY (1) MY190257A (en)
NI (1) NI201400122A (en)
NZ (1) NZ701205A (en)
PE (1) PE20150226A1 (en)
PH (1) PH12014502314A1 (en)
SG (1) SG11201406492YA (en)
WO (1) WO2013156488A2 (en)
ZA (1) ZA201407370B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498815B (en) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 Chemical modifier of recombinant human kallikrein and application thereof
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
FR3034669B1 (en) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies NEW USE OF THE VON WILLEBRAND FACTOR
US20180169297A1 (en) * 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
CN109998994B (en) * 2018-02-13 2021-12-07 四川大学 Flexible liposome containing medicine and preparation method thereof
CN114929261A (en) 2020-02-17 2022-08-19 生物测试股份公司 Subcutaneous administration of factor VIII

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (en) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU5858690A (en) * 1989-06-14 1991-01-08 Cetus Corporation Polymer/antibiotic conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
JP3866279B2 (en) 1992-09-28 2007-01-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド Novel reagents for peptide ligation
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (en) * 1994-09-29 1996-04-09 Teijin Ltd Human activated protein c derivative
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
JPH08325270A (en) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co Polymer prodrug against beta-lactamase and its use
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
WO1999043357A1 (en) * 1998-02-25 1999-09-02 Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers
CA2397347C (en) * 2000-02-11 2011-07-12 Maxygen Aps Factor vii or viia-like molecules
ES2449224T3 (en) 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Subcutaneous administration of Coagulation Factor VII
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
KR101186140B1 (en) * 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Pegylated factor vii glycoforms
MXPA04012496A (en) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms.
AU2004215912B2 (en) * 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US20130137157A1 (en) * 2003-04-09 2013-05-30 Novo Nordisk A/S Glycopegylated factor vii and factor viia
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
KR100760448B1 (en) 2004-03-04 2007-10-04 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition Containing Benzamidine Derivative and Method for Stabilizing Benzamidine Derivative
KR101100059B1 (en) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 Polymer-factor ix moiety conjugates
EP1778838A2 (en) 2004-08-02 2007-05-02 Novo Nordisk Health Care AG Conjugation of fvii
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
CN102719508A (en) * 2005-08-19 2012-10-10 诺和诺德公司 Glycopegylated factor VII and factor VIIA
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
CN101557830B (en) 2006-12-15 2016-06-08 巴克斯特国际公司 There is the factor VIIa-Polysialic acid conjugate of the Half-life in vivo of prolongation
JP5702066B2 (en) * 2006-12-27 2015-04-15 ネクター セラピューティクス Polymer conjugates of von Willebrand factor and factor VIII having dissociable linkages
JP5558106B2 (en) 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー Subcutaneous administration of coagulation factor VII-related polypeptide
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
NZ579985A (en) 2007-04-13 2012-02-24 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof
EP2014299A1 (en) 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
WO2009047500A1 (en) 2007-10-09 2009-04-16 Polytherics Limited Novel conjugated proteins and peptides
US8552046B2 (en) 2007-10-16 2013-10-08 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor VIIa modulator
EP2626080A3 (en) 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
TWI538916B (en) 2008-04-11 2016-06-21 介控生化科技公司 Factor vii polypeptides that are modified and uses thereof
EP2282767A4 (en) * 2008-04-16 2012-07-11 Bayer Healthcare Llc Site-directed modification of factor ix
US20110183906A1 (en) * 2008-04-24 2011-07-28 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
JP5642065B2 (en) * 2008-05-23 2014-12-17 ノボ ノルディスク ヘルス ケア アーゲー Low viscosity composition comprising pegylated GLA-domain containing protein
JP5622117B2 (en) 2008-07-21 2014-11-12 ポリテリクスリミテッド Novel reagents and methods for conjugating biomolecules
WO2010045321A2 (en) * 2008-10-15 2010-04-22 Baxter International Inc. Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
MX2011004085A (en) * 2008-10-17 2011-09-27 Baxter International Modified blood factors comprising a low degree of water soluble polymer.
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
KR101832937B1 (en) * 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 Blood coagulation protein conjugates
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP4023247A1 (en) * 2010-07-30 2022-07-06 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
WO2012088123A1 (en) * 2010-12-22 2012-06-28 Nektar Therapeutics Polymer-factor vii moiety conjugates

Also Published As

Publication number Publication date
ECSP14023048A (en) 2015-11-30
CA2869993A1 (en) 2013-10-24
MY190257A (en) 2022-04-11
MD20140123A2 (en) 2015-04-30
EA201491702A1 (en) 2015-03-31
CN104411335A (en) 2015-03-11
EP2838566A2 (en) 2015-02-25
MX2014012512A (en) 2015-01-15
JP2018024684A (en) 2018-02-15
IL235129B (en) 2022-06-01
JP6550107B2 (en) 2019-07-24
US20180036229A1 (en) 2018-02-08
MX2020014208A (en) 2021-03-09
PE20150226A1 (en) 2015-02-14
IN2014DN08598A (en) 2015-05-22
BR112014025737A2 (en) 2017-07-04
AU2018200111B2 (en) 2019-11-07
GEP201706716B (en) 2017-08-10
CO7151496A2 (en) 2014-12-29
GB201910184D0 (en) 2019-08-28
GB2516388A (en) 2015-01-21
EA033469B1 (en) 2019-10-31
NZ701205A (en) 2016-02-26
WO2013156488A3 (en) 2014-01-16
CR20140475A (en) 2015-01-23
AU2013248296A1 (en) 2014-11-13
KR20140146171A (en) 2014-12-24
IL235129A0 (en) 2014-12-31
US20150086524A1 (en) 2015-03-26
AU2018200111A1 (en) 2018-01-25
CL2014002773A1 (en) 2015-01-16
GB201418864D0 (en) 2014-12-03
JP2019131593A (en) 2019-08-08
WO2013156488A2 (en) 2013-10-24
NI201400122A (en) 2016-12-02
ZA201407370B (en) 2017-09-27
KR102137290B1 (en) 2020-07-23
PH12014502314B1 (en) 2015-01-12
HK1200695A1 (en) 2015-08-14
CA2869993C (en) 2023-05-23
PH12014502314A1 (en) 2015-01-12
AU2020200842A1 (en) 2020-02-27
AP2014008049A0 (en) 2014-11-30
US11351112B2 (en) 2022-06-07
JP2015512927A (en) 2015-04-30
GB201910190D0 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
HK1203963A1 (en) Novel therapeutic agents
HK1211475A1 (en) Combination therapy
GB201212513D0 (en) Therapeutic agents
ZA201305897B (en) Combination therapy
EP2906208A4 (en) Therapeutic treatment
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
ZA201400120B (en) Combination therapy
GB201217439D0 (en) Combination therapy
GB201217704D0 (en) Therapeutic agents
GB201207305D0 (en) Therapy
EP2701744A4 (en) Combination therapy
HK1210426A1 (en) Combination therapy
IL228589A0 (en) Therapeutic treatment
IL238174A0 (en) Combination therapy with volasertib
EP2804853A4 (en) Therapeutic uses
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201214454D0 (en) Therapeutic treatments
GB201214456D0 (en) Therapeutic treatments
GB201211543D0 (en) Combination therapy
GB201110895D0 (en) Therapeutic use